Current antineoplastic treatments are not sufficient to cure cancer, in part due to lack efficacy and/or selectivity. Further, they often display significant side effects calling for new therapeutic approaches.
The invention consists in the design, realization and administration of peptides that target hexokinase 2 (HK2) specifically in tumors and display antineoplastic activity.
HK2 is glycolytic enzyme that contributes to metabolism, growth and death inhibition of tumor cells. Its expression is associated with poor prognosis and chemotherapeutic/radiation resistance in diverse solid and hematopoietic tumors.

TRL (Technology Readiness Level)

Lead Optimization/Preclinical

Inventors

Andrea
Rasola

Francesco
Ciscato

Paolo
Bernardi

Download the brochure

  • A compound to mitigate the cytokine storm

    The body’s inflammatory response to fight infections and in tissue repair processes is crucial for normal functioning of the body. Yet, if not controlled, it can cause severe injury to the human body, as occurs during cytokine storm, a potentially[...]

  • Tioridazine analogues for acute myeloid leukemia treatment

    Specific treatments for (pediatric) acute myeloid leukemia (AML) are lacking. Standard treatments still include intensive myelosuppressive chemotherapy, which is unsatisfactory in terms of general toxicity, with the persistent risk of relapse due to the escape of quiescent leukemic cells to[...]

  • A treatment for fibrotic disease

    Fibrosing diseases are chronic pathologies, with a different genesis, characterized by various types of cellular or extracellular infiltrates determining a progressive destruction of the parenchyma, which is replaced by fibrous tissue, causing progressive damage to organ anatomy. Fibrosing diseases are[...]

Subscribe to newsletter

Follow the activities promoted by UniSMART Foundation